Literature DB >> 8113811

SK-N-BE: a human neuroblastoma cell line containing two subtypes of delta-opioid receptors.

J Polastron1, M Mur, H Mazarguil, A Puget, J C Meunier, P Jauzac.   

Abstract

A human neuroblastoma cell line, SK-N-BE, was shown to express a substantial amount of opioid receptors (200-300 fmol/mg of protein). A ligand binding profile of these receptors revealed that they could belong to two distinct subtypes of delta-opioid receptors. Results from sucrose-gradient sedimentation experiments were compared with similar data obtained with the mu-opioid receptor of the rabbit cerebellum and the delta-opioid receptor of the hybrid NG108-15 cell line and have shown that the opioid receptor of the SK-N-BE cell line behaved hydrodynamically as an intermediate between mu- and delta-opioid receptors. Taken together, pharmacological and hydrodynamic studies suggest that the opioid receptors present in the SK-N-BE cell membranes could belong to two delta-opioid receptor subtypes interacting allosterically. Functional experiments suggest that at least one of these subtypes of delta-opioid receptor is negatively coupled to the adenylate cyclase via a Gi protein and that the opiate receptors of the SK-N-BE neuroblastoma cell line undergo a rapid down-regulation when preincubated in the presence of the high-affinity opioid, etorphine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8113811     DOI: 10.1046/j.1471-4159.1994.62030898.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

Review 1.  Identifying ligand-specific signalling within biased responses: focus on δ opioid receptor ligands.

Authors:  I Charfi; N Audet; H Bagheri Tudashki; G Pineyro
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 2.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

3.  ßarrestin1-biased agonism at human δ-opioid receptor by peptidic and alkaloid ligands.

Authors:  Benjamin Aguila; Laurent Coulbault; Audrey Davis; Nicolas Marie; Ahmed Hasbi; Florian Le bras; Géza Tóth; Anna Borsodi; Vsevolod V Gurevich; Philippe Jauzac; Stéphane Allouche
Journal:  Cell Signal       Date:  2011-11-09       Impact factor: 4.315

4.  Differential G-protein activation by alkaloid and peptide opioid agonists in the human neuroblastoma cell line SK-N-BE.

Authors:  S Allouche; J Polastron; A Hasbi; V Homburger; P Jauzac
Journal:  Biochem J       Date:  1999-08-15       Impact factor: 3.857

5.  In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance.

Authors:  B Aguila; L Coulbault; M Boulouard; F Léveillé; A Davis; G Tóth; A Borsodi; G Balboni; S Salvadori; P Jauzac; S Allouche
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

Review 6.  The delta opioid receptor tool box.

Authors:  Ana Vicente-Sanchez; Laura Segura; Amynah A Pradhan
Journal:  Neuroscience       Date:  2016-06-24       Impact factor: 3.590

7.  Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells.

Authors:  Céline Kerros; Thibault Cavey; Brigitte Sola; Philippe Jauzac; Stéphane Allouche
Journal:  J Exp Clin Cancer Res       Date:  2009-06-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.